Amsbio Introduces Novel HAMA Blocker for Reduction of Immunoassay Interference

16 Dec 2009
Sarah Sarah
Marketing / Sales

Product news

Amsbio has introduced TRU Block, a highly potent reagent that actively blocks the heterophilic antibody (HA) interference in immunoassays including but not limited to Human Anti-Mouse Antibody (HAMA) interference.

Heterophilic antibodies are a group of human antibodies against animal IgG. HA interference is a well known interference factor in diagnostic assays, often causing false positive or false negative results. The frequency of such interference is low, but false results have significant impact on the quality and competitiveness of the diagnostic assays as well as on the lives of those individuals who have been falsely diagnosed.

TRU Block offers many advantages over traditional Mouse IgG reagents which inhibit HAMA by serving as antigens of HAMA. TRU Block works differently using a proprietary active mechanism and is 5-20 times more effective than Mouse IgG on HAMA blocking thereby reducing your blocker usage. Beneficially TRU Block works well on HAMA as well as other types of HA while Mouse IgG is effective only on HAMA.

Extensive quality control (including a HAMA blocking functional assay, purity and bioburden testing) ensures that every batch of TRU Block is well characterized. Guaranteed as greater than 95% pure - the high purity of TRU Block delivers highly consistent performance. Excellent lot-to-lot consistency further reduces the need for adjusting assay reagents to optimize performance.

Links

Tags

Assay AssemblyAssay Assembly is technique used in drug discovery to develop assays to test the cytotoxicity, genotoxicity, or other activities of a compound on a cell. Assay assembly requires chip assembly, a delivery system and a detection and analysis method. Beneficial features of assay kits or automated systems include high-throughput, high speed and sensitivity and low signal to noise ratio.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.
Amsbio Introduces Novel HAMA Blocker for Reduction of Immunoassay Interference